Live Breaking News & Updates on Karolinska Development Ab Nasdaq Stockholm|Page 3

Stay updated with breaking news from Karolinska development ab nasdaq stockholm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product

STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93% spinal fusion rate at 12 months as assessed with CT by independent radiological review after surgery with the novel nanosynthetic bone graft OssDsign Catalyst. The data, that has been submitted to a peer-reviewed scientific journal, indicates that the use of OssDsign Catalyst lead ....

Karolinska Institutet , Johan Dighed , Viktor Drvota , Investment Fund , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Buda Health Clinic , Drug Administration , National Center , Nasdaq Stockholm , Ossdsign Catalyst , Spinal Disorders , Dsign Catalyst , Nasdaq First North Growth Market , General Counsel ,

Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates

STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary. ....

Karolinska Institutet , Johan Dighed , Viktor Drvota , Drug Administration , Karolinska Development , Karolinska Development Ab Nasdaq Stockholm , Investment Fund , Nasdaq Stockholm , Ossdsign Catalyst , Ossdsign Cranial , Dsign Catalyst , Nasdaq First North Growth Market , General Counsel ,

Karolinska Development's portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | 04.12.23

Karolinska Development's portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration | 04.12.23
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United States , Karolinska Institutet , Johan Dighed , Emily Jutkiewicz , Viktor Drvota , University Of Michigan , Karolinska Development Ab Nasdaq Stockholm , Professor Amynah Pradhan At Washington University , Us National Institute Of Drug Abuse , Karolinska Development , Nasdaq Stockholm , Drug Abuse , Delta Opioid Receptor Agonist , Professor Amynah Pradhan , Washington University , General Counsel ,

Karolinska Development's portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration

Karolinska Development's portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United States , Emily Jutkiewicz , Viktor Drvota , Karolinska Institutet , Johan Dighed , Us National Institute Of Drug Abuse , Professor Amynah Pradhan At Washington University , University Of Michigan , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Nasdaq Stockholm , Drug Abuse , Delta Opioid Receptor Agonist , Professor Amynah Pradhan , Washington University , General Counsel ,

Karolinska Development's portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis

Karolinska Development's portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Viktor Drvota , Karolinska Institutet , Johan Dighed , Karolinska Development , Liver International , Karolinska Development Ab Nasdaq Stockholm , Nasdaq Stockholm , Umecrine Cognition , General Counsel ,